Skip to main content
Premium Trial:

Request an Annual Quote

Startup MDx Firm Multiplicom Raises $3M in Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Belgian molecular diagnostics startup Multiplicom has received €2 million ($3 million) in a funding round, the company said this week.

Investors included Belgian venture capital firm Gimv, Gimv-managed Biotechfonds Vlaanderen, life science research institute VIB, and the University of Antwerp.

Proceeds will be used to develop diagnostic tests, get CE marking for them, and to commercialize them, Multiplicom said.

Multiplicom is a spinout of Jurgen Del-Favero's laboratory at the VIB department of molecular genetics at the University of Antwerp and is developing tests to determine whether individuals have increased risk for certain diseases, to detect congenital genetic defects, and to identify the most appropriate treatments.

The company has developed assays for breast cancer and cystic fibrosis.

The initial focus of the firm will be on creating a direct sales force covering Western Europe and a distribution channel in other nations. Multiplicom also has agreements with pharmaceutical firms to use its multiplex PCR technology called Multiplexer to identify genetic biomarkers linked to drug safety and efficacy, it said.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.